Application of rhBMP in spinal fusion surgery: any correlation of cancer incidence? A systematic review and meta-analysis

Wijaya, Jeremiah Hilkiah; Tjahyanto, Teddy; Alexi, Roberto; Purnomo, Alexander Erick; Rianto, Louis; Arjuna, Yang Yang Endro; Tobing, Jephtah Furano Lumban; Yunus, Yesaya; Faried, Ahmad

doi:10.1007/s00586-023-07730-4

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both in vitro and in vivo studies have shown a pro-oncogenic effect of the protein ( Skovrlj et al, 2015 ). However, clinical trials of BMP-2 materials found no evidence of de novo tumor formation, and a meta-analysis could not confirm an increased risk of cancer after protein use ( Wijaya et al, 2023 ). The disadvantages described above significantly impact the direction of further protein therapy development ( Table 1 ).…”

Section: Bone Graft Materials With Bmp-2 In Dentistry and Maxillofaci...mentioning

confidence: 99%

Application of BMP-2 and its gene delivery vehicles in dentistry

Kuznetsova,

Vasilyev,

Bukharova

et al. 2024

The Saudi Dental Journal

View full text Add to dashboard Cite

Section: Bone Graft Materials With Bmp-2 In Dentistry and Maxillofaci...mentioning

confidence: 99%

Application of BMP-2 and its gene delivery vehicles in dentistry

Kuznetsova,

Vasilyev,

Bukharova

et al. 2024

The Saudi Dental Journal

View full text Add to dashboard Cite

“…However, several studies have reported that using BMP is not associated with cancer risk or mortality [ 6 , 59 , 60 ]. The most recent meta-analysis of the correlation between rhBMP application and cancer incidence also found that rhBMP was not associated with an increased risk of cancer within the cohort [ 61 ]. However, when looking closely at the results of this meta-analysis, the risk ratio of the rhBMP group compared to the control group was 1.85; therefore, it cannot be said that there is no risk.…”

Section: Safety and Limitation Of Rhbmp-2mentioning

confidence: 99%

Current Status of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) in Maxillofacial Surgery: Should It Be Continued?

On,

Park,

et al. 2023

Bioengineering

View full text Add to dashboard Cite

Recombinant human bone morphogenetic protein-2 (rhBMP-2) has shown potential in maxillofacial surgery owing to its osteoinductive properties. However, concerns about its safety and high cost have limited its widespread use. This review presents the status of rhBMP-2 use in maxillofacial surgery, focusing on its clinical application, efficacy, safety, and limitations. Studies have demonstrated rhBMP-2’s potential to reduce donor site morbidity and increase bone height in sinus and ridge augmentation; however, it may not outperform autogenous bone grafts. In medication-related osteonecrosis of the jaw treatment, rhBMP-2 has been applied adjunctively with promising results, although its long-term safety requires further investigation. However, in maxillofacial trauma, its application is limited to the restoration of large defects. Safety concerns include postoperative edema and the theoretical risk of carcinogenesis. Although postoperative edema is manageable, the link between rhBMP-2 and cancer remains unclear. The limitations include the lack of an ideal carrier, the high cost of rhBMP-2, and the absence of an optimal dosing regimen. In conclusion, rhBMP-2 is a promising graft material for maxillofacial surgery. However, it has not yet become the gold standard owing to safety and cost concerns. Further research is required to establish long-term safety, optimize dosing, and develop better carriers.

show abstract